


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**C-MER 希瑪**

**C-MER EYE CARE HOLDINGS LIMITED**

**希瑪眼科醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3309)**

**POSITIVE PROFIT ALERT  
FOR THE SIX MONTHS ENDED 30 JUNE 2019**

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of C-MER Eye Care Holdings Limited (the “**Company**” which together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on the information currently available to the Board, which includes, but without limitation to, the unaudited consolidated management accounts of the Group for the five months ended 31 May 2019, the Directors wish to inform the shareholders (the “**Shareholders**”) and prospective investors of the Company that the net profit of the Group for the six months ended 30 June 2019 would substantially increase by more than 100% for the period, as compared with the financial results of the Group for the six months ended 30 June 2018, primarily because of the following factors:

- (1) significant increase in the amount of revenue of the Group of more than 30% as compared with the five months ended 31 May 2019;
- (2) decrease in the amount of net loss of the Group’s eye hospital in Beijing which commenced business operations in January 2018; and
- (3) decrease in the amount of foreign exchange loss arising from the decreased bank deposits denominated in Renminbi.

Nonetheless, the above positive impact is partly offset by net loss incurred by the satellite clinic in Baoan district in Shenzhen, which commenced business operations in November 2018, and the eye hospital in Kunming, which has been acquired by the Group since 28 March 2019.

As the Company is still in the process of finalising the results for the six months ended 30 June 2018, the information contained in this announcement is based on the management's preliminary review on the unaudited consolidated management accounts of the Group for the five months ended 31 May 2019 and current information available to the Board and has not been reviewed and confirmed by the Company's auditors or the audit committee of the Board. Shareholders and potential investors of the Company are advised to read carefully the interim results announcement of the Company for the six months ended 30 June 2019 which is expected to be published by the end of August 2019.

**Shareholders and prospective investors of the Company are advised to exercise caution when dealings in the shares of the Company.**

By order of the Board

**C-MER EYE CARE HOLDINGS LIMITED**

**Dr. LAM Shun Chiu Dennis**

*Chairman and Chief Executive Officer and Executive Director*

Hong Kong, 2 July 2019

*As of the date of this announcement, the Board comprises four executive Directors, namely Dr. LAM Shun Chiu Dennis, Ms. LI Xiaoting, Dr. LEE Yau Wing Vincent and Mr. LI Chunshan and five independent non-executive Directors, namely Dr. LAU Johnson Yiu-Nam, Dr. LI Kwok Tung Donald, Mr. MA Andrew Chiu Cheung, Mr. CHAN Chi Leong and Ms. BENTLEY Annie Liang.*